Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

View the other Modules in this CSPE Core Curriculum Series:
  
Cystic Fibrosis Module #1: Cystic Fibrosis: An Overview for Pharmacists ►

Cystic Fibrosis Module #2: Chronic Medications: Changing the Course of Cystic Fibrosis ►

Cystic Fibrosis Module #3: Management of Acute Pulmonary Exacerbations: Pseudomonas and Beyond ►

 

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities►

Activity Description

Cystic Fibrosis (CF) is an inherited chronic disease caused by a gene defect. It is estimated to occur in about 1 in every 3500 children born in the United States. This complex disease can affect the lungs, the digestive system, and other organs resulting in a high morbidity and mortality. CF can also affect the pharmacokinetics of many drugs and this needs to be considered when prescribing medications to CF patients. CF has no known cure, but treatments are available to help modify the disease process. The modules of this program will provide information on the disease and treatments for the CF patient as well as address other important challenges and considerations in CF patients. Module 4 discusses the importance of adherence in CF patients and will address the role of education to improve the treatment of CF patients.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

• Describe medication adherence barriers faced by CF patients
• Explain features of innovative pharmacy-based management strategies that are associated with improving adherence, outcomes, and cost management in patients with CF
• Describe the medication access programs available for CF patients

Faculty

David Young, PharmD
Professor of Pharmacotherapy (Clinical)
PGY-2 Pharmacy Residency in Internal Medicine Director
University of Utah College of Pharmacy
Salt Lake City, Utah

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. David Young does not have any relevant commercial and/or financial relationships to disclose.

CE Accreditation

Release Date: May 15, 2020
Expiration Date: May 15, 2023

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-215-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.